Inflamed minds: How traumatic brain injury rewires the brain for addiction

Traumatic brain injury (TBI) remains a silent epidemic, affecting more than 50 million people globally each year and contributing to nearly one-third of injury-related deaths. Beyond the initial physical trauma, TBI survivors often face long-term neurological and behavioral challenges, from memory and mood disorders to an increased vulnerability to substance abuse. But the biological mechanisms linking head injury to alcohol misuse have remained largely elusive.

A new study from researchers at Texas A&M Health, published in Translational Psychiatry, uncovers a critical piece of this puzzle: Traumatic brain injury triggers neuroinflammation that disrupts the brain’s cholinergic system, a key network governing cognition, motivation and impulse control. This inflammation-driven disruption, in turn, increases alcohol consumption and impairs cognition.

The multidisciplinary team led by Jun Wang, PhD, and Lee A. Shapiro, PhD, in the Texas A&M University Naresh K. Vashisht College of Medicine, used an integrative approach, spanning behavioral neuroscience, electrophysiology and immunohistochemistry. Their work was sponsored by the National Institute of Alcohol and Alcoholism (NIAAA) and the National Institute of Neurological Disorders and Stroke (NINDS).

Clinicians have long observed that individuals with a history of TBI are more likely to develop alcohol use disorders.

“Previous work from our lab had already established that the brain region, dorsomedial striatum (DMS), critically regulates alcohol drinking and cognitive flexibility. Whether TBI leads to any striatal modifications to affect these functions was not known,” said Himanshu Gangal, PhD, first author of the study.

The team hypothesized that microglial activation, one of the brain’s primary immune responses, might suppress the function of cholinergic interneurons (CINs) within the dorsomedial striatum, a brain region critical for cognitive flexibility. When these neurons underperform, it could lead to both cognitive inflexibility and heightened alcohol-seeking behavior, two hallmarks of addiction vulnerability.

Using a fluid percussion injury (FPI) model to simulate TBI in animal models that consumed alcohol, they observed heightened alcohol preference and cognitive deficits. Fluorescent labeling and slice recordings showed a decrease in the number and activity of CINs. Acetylcholine biosensor imaging confirmed a “hypo-cholinergic” state, marked by reduced spontaneous acetylcholine release in the dorsomedial striatum.

“This reduction in the striatal cholinergic tone could be the key driver behind post-injury cognitive and alcohol consumption disturbances,” Wang said.

The researchers found persistent microglial activation in the striatum post-TBI, without significant astrocyte activity changes. This chronic inflammatory response mirrors findings from human brain imaging after severe TBI, suggesting that microglia, not astrocytes, sustain long-term circuit disruption. When the researchers treated naive animal models with PLX5622, a compound that depletes microglia, they observed enhanced firing of cholinergic interneurons and upregulated acetylcholine release in the striatum. This suggests that reducing microglial activity could potentially normalize cholinergic signaling and curb alcohol-seeking behavior after TBI.

“The microglia are like double-edged swords. While they rush to protect the brain after injury, prolonged activation can become toxic and disrupt neural circuitry,” Shapiro said.

The implications of this work extend beyond basic neuroscience. Alcohol misuse after brain injury is a major barrier to recovery, compounding cognitive deficits and increasing the risk of further injury. By highlighting microglial-cholinergic interaction as a link between TBI and alcohol use disorder, this study paves the way for new treatments.

The researchers see a variety of clinical applications for these findings, such as medications that suppress microglia, enhance cholinergic activity or use non-invasive brain stimulation to rebalance striatal signaling.

“Our study reframes how we think about post-TBI complications not just as behavioral issues, but as neurobiological consequences of inflammatory rewiring,” Gangal said.

The next steps for the Wang and Shapiro labs are to translate these insights into region- and pathway-specific interventions. The researchers note that although pharmacological microglial depletion shows promise, they need to identify the specific immune cells and neuroinflammatory pathways that contribute to the observed post-TBI changes.

“Future work will employ targeted gene or viral tools to modulate microglial activity specifically in the striatum, as well as multi-region brain mapping to explore how TBI disrupts communication across the cortex, hippocampus and amygdala,” Wang said.

Together, these findings highlight a powerful new link between brain injury, inflammation and addiction, revealing how trauma can rewire neural circuits long after the initial event. By pinpointing microglia as both the culprit and a potential therapeutic target, the study opens the door to innovative treatments aimed at restoring cognitive balance, reducing alcohol vulnerability and improving recovery outcomes for TBI survivors.